Understanding how certain immune cells can improve treatment for pancreatic cancer
Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity
This study is looking at how certain immune cells can help boost the body's defense against pancreatic cancer, especially in cases where the tumors don't have many T cells, which are important for fighting cancer. By comparing immune cells from people who have survived longer with those who haven't, the researchers hope to find new ways to activate the immune system and create better treatments for pancreatic cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10904895 on NIH RePORTER |
What this research studies
This research investigates the role of group 2 innate lymphoid cells (ILC2s) in enhancing the immune response against pancreatic cancer, particularly in tumors that lack T cells, known as 'cold' tumors. By comparing immune cells in tumors from long-term survivors to those from short-term survivors, the study aims to identify new immunotherapy targets that could activate the immune system in these challenging cases. The researchers utilize mouse models to explore how ILC2s can recruit other immune cells to stimulate CD8+ T cells, which are crucial for fighting cancer. The ultimate goal is to develop effective treatments for pancreatic ductal adenocarcinoma (PDAC), a type of cancer that currently has very few effective therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with 'cold' tumors that have low T cell presence.
Not a fit: Patients with other types of cancer or those whose tumors are already responsive to current immunotherapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy options for patients with pancreatic cancer, significantly improving their chances of survival.
How similar studies have performed: While the approach of targeting ILC2s in pancreatic cancer is relatively novel, previous studies have shown promise in enhancing immune responses in other cancer types.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Balachandran, Vinod P — Sloan-Kettering Inst Can Research
- Study coordinator: Balachandran, Vinod P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.